This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
L02BX Other hormone antagonists and related agents
RX_L02BX
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
1742 |
4. Check minimum number of events
Min. number of events
3
|
1742 |
5. Include endpointsNone |
1742 |
6. Filter based on genotype QC (FinnGen only) |
1742 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF3
Similar endpoints
↥List of similar endpoints to
L02BX Other hormone antagonists and related agents
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of prostate
- malignant neoplasm of male genital organs
- Malignant neoplasm of prostate, excluding all cancers (controls excluding all cancers)
- malignant neoplasm of male genital organs, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 1742 | - | 1742 |
| Unadjusted period prevalence (%) | 0.77 | - | 0.77 |
| Median age at first event (years) | 73.35 | - | 73.35 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 1484
- Matched controls
- 14841
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
26.0
323.0
509
292
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
13.5
323.0
1069
2379
L02AE02
ATC
leuprorelin; implant, parenteral
19.2
323.0
753
753
L02BX02
ATC
degarelix; parenteral
2759.9
323.0
1144
19
116
Kela drug reimbursment
Prostate cancer
4432.6
323.0
1480
1052
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
236.2
323.0
1444
1966
H02AB02
ATC
dexamethasone; systemic
15.1
323.0
644
715
352
Kela drug reimbursment
Abiraterone and enzalutamide
184.0
323.0
485
39
Y77
ICPC
Malignant neoplasm prostate
52.9
323.0
915
437
L02BB03
ATC
bicalutamide; oral
22.1
323.0
593
434
C61
ICD-10 Finland
Malignant neoplasm of prostate
1613.2
323.0
1478
2042
M05BX04
ATC
denosumab; parenteral
65.1
323.0
639
170
163
Kela drug reimbursment
Abiraterone and enzalutamide
271.4
323.0
746
55
L02BB04
ATC
enzalutamide; oral
189.5
323.0
543
45
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
62.4
323.0
533
132
L02BX03
ATC
abiraterone; oral
996.4
323.0
563
9
KE1AT
NOMESCO Finland
Biopsy of prostata with ultrasoudnguidance
11.0
312.4
702
1116
NK6AN
NOMESCO Finland
Total body bone isotope imaging
23.1
296.1
444
269
WF049
NOMESCO Finland
Radiotherapy of metastasis
20.3
280.2
440
301
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
84.2
253.1
281
41
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
20.5
249.2
388
252
A03FA01
ATC
metoclopramide; systemic, rectal
7.5
233.5
678
1488
WD205
NOMESCO Finland
Therapy of methastized malignancy with hormones
138.1
231.3
243
21
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
5.8
212.2
910
3197
JN4BD
NOMESCO Finland
Extensive body CT
7.0
199.1
588
1264
XX3DW
NOMESCO Finland
Time consuming IT work
7.7
196.7
532
1005
Z51.5
ICD-10 Finland
Palliative care
8.8
182.3
435
665
WF002
NOMESCO Finland
Radical radiotherapy
8.6
181.2
442
700
JN4AD
NOMESCO Finland
Body CT examination
7.3
163.4
447
827
N02AA05
ATC
oxycodone; systemic
5.4
157.5
592
1630
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
13.8
153.1
277
243
XKD00
NOMESCO Finland
Uroflowmetry
4.4
152.1
857
3536
ZX112
NOMESCO Finland
Subcutaneous
17.8
146.5
237
157
3054
Kela drug reimbursment
NA
69.3
140.5
161
26
1523
Kela drug reimbursment
NA
69.3
140.5
161
26
KE3AT
NOMESCO Finland
Transrectal gold marker implantation in prostate under ultrasound guidance
10.5
139.4
290
335
L03AA13
ATC
pegfilgrastim; parenteral
17.9
136.1
219
142
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
9.0
128.9
295
400
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
4.0
128.0
710
2746
A04AA02
ATC
granisetron; systemic, transdermal
9.1
125.8
285
379
R74.8
ICD-10 Finland
Abnormal levels of other serum enzymes
5.5
122.3
420
995
L03AA14
ATC
lipegfilgrastim; parenteral
41.2
118.5
149
40
SPAT1256
SPAT
Intramuscular and subcutaneous injection
3.6
117.8
969
5075
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
25.8
114.4
162
70
WF004
NOMESCO Finland
Palliative radiotherapy
12.5
105.6
198
181
L02AE04
ATC
triptorelin; parenteral
17.6
89.7
144
90
XX7FT
NOMESCO Finland
Radioyttrium therapy with connected antibody
297.8
83.5
84
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
10.8
82.9
166
171
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
10.6
82.1
166
174
L02AE03
ATC
goserelin; implant
18.0
81.2
129
78
D40.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Prostate
9.2
80.5
177
216
1CD02
NOMESCO Finland
NA
128.7
79.8
85
7
R86.0
ICD-10 Finland
Abnormal findings in specimens from male genital organs, abnormal level of enzymes
6.8
77.5
209
349
ZX090
NOMESCO Finland
Other technic of radiotherapy
9.1
73.1
161
196
A79
ICPC
Malignancy NOS
17.9
69.3
110
66
C77.8
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph nodes of multiple regions
37.3
68.8
88
25
YJ2VG
NOMESCO Finland
MRI examination of pelvis with high intensity magnet for dose design of radiotherapy
9.3
62.3
134
156
WZC30
NOMESCO Finland
Teaching
3.3
61.6
366
1333
TKE00
NOMESCO Finland
Needle biopsy of prostate
3.9
57.5
262
767
H02AB06
ATC
prednisolone; systemic
2.4
54.9
838
5248
M87.1
ICD-10 Finland
Osteonecrosis due to drugs
49.2
54.7
66
14
G03HA01
ATC
cyproterone; systemic
15.1
53.4
90
63
KE1BE
NOMESCO Finland
Rectal ultrasound examinaiton of prostata
2.8
52.4
415
1809
NK6AQ
NOMESCO Finland
Whole body bone SPET with low dose CT
30.1
51.4
69
24
2BX02
NOMESCO Finland
NA
43.1
50.1
62
15
XX7AT
NOMESCO Finland
Radiation therapy with Radium-223
504.0
49.7
49
*
C77.5
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intrapelvic lymph nodes
35.1
49.5
64
19
ZX120
NOMESCO Finland
Intravenous
3.4
47.2
258
866
R33
ICD-10 Finland
Retention of urine
2.9
46.9
332
1336
YN7BD
NOMESCO Finland
Extensive CT examination of spine for dose design of radiotherapy
32.8
45.8
60
19
A06AH03
ATC
naloxegol; oral
12.0
45.6
85
75
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.9
45.1
325
1319
XJH00
NOMESCO Finland
Transanal ultrasonography
2.9
44.9
317
1270
J01MA02
ATC
ciprofloxacin; systemic
2.2
44.4
769
4909
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
6.8
44.4
116
182
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
7.0
42.9
110
168
A04AA01
ATC
ondansetron; systemic, rectal
4.3
42.8
168
423
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
4.5
42.8
160
384
Y06
ICPC
Prostate symptom/complaint
4.0
42.6
183
501
WD215
NOMESCO Finland
Multiple therapy of methastized malignancy with hormones
115.9
42.0
45
*
JN4LR
NOMESCO Finland
Extensive PET-CT of receptors in whole body
35.0
41.8
54
16
SPAT1254
SPAT
Administration of medicine
2.7
41.7
323
1363
C77.2
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intra-abdominal lymph nodes
23.6
41.2
59
26
JN5ER
NOMESCO Finland
PET-CT of receptors in whole body
13.2
41.1
73
58
H02AB07
ATC
prednisone; oral
2.9
41.0
289
1148
XX9AN
NOMESCO Finland
Complementary isotope examination or additional picture
50.6
40.9
49
10
G04CA02
ATC
tamsulosin; oral
2.1
39.0
830
5659
XX1XQ
NOMESCO Finland
Other SPECT-CT
108.0
38.9
42
*
ZX080
NOMESCO Finland
Image guided radiotherapy
8.5
38.3
86
107
NK6BQ
NOMESCO Finland
Whole body extensive bone SPET with low dose CT
16.1
38.1
62
40
A02BC02
ATC
pantoprazole; systemic
2.1
38.0
1012
7517
WW500
NOMESCO Finland
Blood transfusion
4.5
37.2
138
327
U77
ICPC
Malignant neopl urinary tract other
28.1
36.1
49
18
PJD64
NOMESCO Finland
Laparoscopic dissection of iliac lymph nodes
7.2
33.4
83
121
YN7AD
NOMESCO Finland
CT examination of spine for dose design of radiotherapy
24.2
33.3
47
20
WB223
NOMESCO Finland
Demanding adjuvant hormone therapy of malignancy
15.5
32.8
54
36
1CD04
NOMESCO Finland
NA
+∞
32.4
31
*
ZXC96
NOMESCO Finland
Robot assisted procedure
4.5
31.5
116
273
WF003
NOMESCO Finland
Adjuvant radiotherapy
4.9
31.3
107
233
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.9
29.9
595
3807
KEB00
NOMESCO Finland
Biopsy of prostate
5.3
29.1
92
184
N02BE01
ATC
paracetamol; systemic, rectal
2.2
28.5
1270
10809
TKE10
NOMESCO Finland
Puncture of prostate
8.7
27.2
59
70
UKC02
NOMESCO Finland
Cystoscopy
2.0
27.1
456
2712
KEC01
NOMESCO Finland
Percutaneous endoscopic radical prostatectomy
3.8
27.1
120
335
WF090
NOMESCO Finland
Profylactic radiotherapy
8.7
26.7
58
69
K62.7
ICD-10 Finland
Radiation proctitis
8.5
25.5
56
68
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
3.5
24.5
120
364
KH1BT
NOMESCO Finland
Urinary tract cathetrisation with X-ray guidance
8.4
24.5
54
66
L03AA02
ATC
filgrastim; parenteral
4.9
24.5
82
175
5BX04
NOMESCO Finland
NA
38.2
24.0
30
8
TNX00
NOMESCO Finland
Puncture and needle biopsy of soft tissue, unspecified region
7.7
23.5
55
74
KH1FT
NOMESCO Finland
Exchange of urinary catheter with radiological guidance
13.7
23.3
40
30
A28
ICPC
Limited function/disability NOS
2.1
22.5
312
1702
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
5.0
21.7
70
144
KFC10
NOMESCO Finland
Bilateral orchiectomy
21.1
21.3
31
15
JN4CD
NOMESCO Finland
Very extensive body CT
3.2
20.9
113
369
WB203
NOMESCO Finland
Simple adjuvant hormone therapy of malignancy
24.6
20.9
29
12
KEC00
NOMESCO Finland
Retropubic radical prostatectomy
3.8
20.7
90
248
ZX013
NOMESCO Finland
Radiotherapy with large shaped fields - SSD therapy
7.9
20.6
47
61
KBV15
NOMESCO Finland
Cystoscopic change of ureteral stent
12.2
20.6
37
31
WVA30
SPAT
NA
4.3
20.2
77
188
B01AB10
ATC
tinzaparin; parenteral
2.7
20.1
144
563
R31
ICD-10 Finland
Unspecified haematuria
2.0
19.9
300
1683
TKC20
NOMESCO Finland
Catheterisation of bladder
2.3
19.5
192
897
XX7JT
NOMESCO Finland
Somatostatin isotope ablative therapy
22.9
19.1
27
12
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.1
19.1
241
1259
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
3.1
18.5
104
349
SPAT1167
SPAT
Insertion of urinary catheter
3.1
18.4
107
368
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
3.2
17.8
96
314
N02AJ06
ATC
codeine and paracetamol; systemic
1.7
17.8
507
3492
TKC22
NOMESCO Finland
Catheterisation instruction
3.4
17.7
89
276
R50.9
ICD-10 Finland
Fever, unspecified
2.0
17.5
245
1331
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.6
17.4
765
5909
ZXC20
NOMESCO Finland
Use of chemical agents
3.9
16.7
70
187
Z03.1
ICD-10 Finland
Observation for suspected malignant neoplasm
3.6
16.6
75
214
Y50
ICPC
Male Genital, Medication/prescr/renewal
16.5
16.6
26
16
WF099
NOMESCO Finland
Other radiotherapy
10.2
16.4
32
32
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.1
16.3
195
990
A50
ICPC
General and Unspecified, Medication/prescr/renewal
3.6
16.3
74
212
J01MA12
ATC
levofloxacin; systemic
1.8
16.3
361
2293
U08
ICPC
Urinary retention
3.6
16.1
74
215
TQX05
NOMESCO Finland
Skin puncture, unspecified location
21.2
16.0
23
11
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
6.7
15.9
40
61
G04BD12
ATC
mirabegron; oral
2.1
15.5
199
1039
PJD44
NOMESCO Finland
Excision of iliac lymph nodes
6.1
15.5
42
71
SPAT1203
SPAT
Injection therapy, other than intramuscular or subcutaneous
3.0
15.5
90
311
M49.5*C79.5
ICD-10 Finland
Metastatic fracture of vertebra
38.5
15.4
19
5
EB1BI
NOMESCO Finland
Cone beam imaging of teeth and jaws (1–2 quarters)
6.3
15.2
40
65
KE1BG
NOMESCO Finland
MRI of prostate
5.7
15.2
43
77
Z51.0
ICD-10 Finland
Radiotherapy session
5.4
14.9
44
83
ZX050
NOMESCO Finland
Stereotactic radiotherapy
6.5
14.5
37
58
L02BB01
ATC
flutamide; oral
9.5
14.5
29
31
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
6.3
14.4
38
62
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
7.8
14.2
32
42
C77.9
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph node, unspecified
30.3
13.9
18
6
KH1YT
NOMESCO Finland
Percutaneous implantation of endoprothesis with radiological guidance
14.9
13.6
22
15
A98
ICPC
Health maint/preventive medicine
1.9
13.6
1329
12184
SPAT1088
SPAT
Blood transfusion
6.9
13.5
33
49
N42.9
ICD-10 Finland
Disorder of prostate, unspecified
3.6
13.4
60
171
J01DB01
ATC
cefalexin; oral
1.6
13.4
1126
9855
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
5.3
13.4
40
77
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.0
13.3
183
984
JN3BD
NOMESCO Finland
Extensive abdominal CT
2.0
13.2
186
1009
EBA10
NOMESCO Finland
Surgical removal of tooth
2.2
13.2
135
639
TPH04
NOMESCO Finland
Cathetrisation of vein
1.7
12.8
343
2282
KE1CG
NOMESCO Finland
Extensive MRI of prostate
5.8
12.7
35
61
ECB20
NOMESCO Finland
Oral alveoplasty
5.6
12.7
36
65
WZB00
NOMESCO Finland
Telephone receipt or other advice
1.7
12.6
326
2146
YN1AD
NOMESCO Finland
CT examination of extremities for dose design of radiotherapy
70.5
12.6
14
*
Y78
ICPC
Malign neopl male genital other
24.5
12.5
17
7
D70.82
ICD-10 Finland
Drug-induced neutropenia
5.5
12.1
35
65
K52.0
ICD-10 Finland
Gastroenteritis and colitis due to radiation
10.1
12.0
23
23
NK6SN
NOMESCO Finland
Bone SPECT
11.8
11.8
21
18
JN2DM
NOMESCO Finland
Lower part of abdomen very extensive MRI examination with Tesla magnet
11.8
11.8
21
18
A06AD11
ATC
lactulose; oral
1.7
11.7
252
1572
KE1DG
NOMESCO Finland
Very extensive MRI of prostate
4.4
11.6
41
95
EB1AI
NOMESCO Finland
Cone beam imaging of teeth and jaws (one quarter)
4.8
11.5
37
78
D63.0
ICD-10 Finland
Anaemia in neoplastic disease
35.3
11.3
14
*
S50
ICPC
Skin, Medication/prescr/renewal
6.0
11.2
30
51
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
4.1
11.1
42
104
XX3AT
NOMESCO Finland
Other labeling with ultrasound guidance
9.3
11.0
22
24
SAA03
NOMESCO Finland
Extended examination of mouth
1.5
11.0
426
3094
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
2.5
10.9
86
357
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
2.0
10.9
137
707
B01AB05
ATC
enoxaparin; parenteral
1.5
10.9
461
3409
KA3EB
NOMESCO Finland
Antegrade pyelography
7.2
10.8
25
35
NE1AA
NOMESCO Finland
Pelvis X-ray examination
2.1
10.6
120
596
KE1DR
NOMESCO Finland
Prostate metabolic PET with CT
14.3
10.5
17
12
XX9AQ
NOMESCO Finland
Supplementary SPECT-CT or additional scan
14.3
10.5
17
12
B03XA02
ATC
darbepoetin alfa; parenteral
3.3
10.5
52
163
U04
ICPC
Incontinence urine
2.6
10.4
77
310
D64.9
ICD-10 Finland
Anaemia, unspecified
1.8
10.4
200
1200
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
3.2
10.4
53
169
U13
ICPC
Bladder symptom/complaint other
3.3
10.3
50
154
A55
ICPC
General and Unspecified, Local injection/infiltration
5.6
10.3
29
53
ZX020
NOMESCO Finland
HDR radiotherapy within tissue
10.7
10.3
19
18
U28
ICPC
Limited function/disability (U)
4.3
10.0
36
86
J01EA01
ATC
trimethoprim; systemic
1.7
9.9
220
1379
KDE20
NOMESCO Finland
Removal of foreign body from urethra
4.2
9.9
36
87
EDW99
NOMESCO Finland
Other operation on mandible
20.2
9.8
14
7
M01AE01
ATC
ibuprofen; systemic, rectal
1.5
9.8
1136
10189
-50
ICPC
Medication/prescr/renewal
2.5
9.8
76
315
WB221
NOMESCO Finland
Demanding neoadjuvant hormone therapy of malignancy
9.6
9.8
19
20
A04AA55
ATC
palonosetron, combinations; systemic
5.3
9.5
28
54
KE002
NOMESCO Finland
Radical radiotherapy of prostata and seminal vesicles
6.7
9.4
23
35
M05BA08
ATC
zoledronic acid; parenteral
30.2
9.4
12
*
XF600
NOMESCO Finland
Bloodpressure measurement
2.0
9.2
112
573
SPAT1154
SPAT
Insertion or removal of subcutaneous medicine capsule
13.8
9.2
15
11
KDV12
NOMESCO Finland
Urethroscopic internal urethrotomy
3.4
9.2
43
130
ZX100
NOMESCO Finland
Oral
3.9
9.1
36
94
G04BE03
ATC
sildenafil; oral
2.7
9.1
59
222
SPAT1263
SPAT
Sampling
1.4
9.1
573
4557
WX408
NOMESCO Finland
General anesthesy, balanced
1.5
8.9
392
2903
L95
ICPC
Osteoporosis
4.7
8.9
29
63
AA3AI
NOMESCO Finland
Cone beam CT of facial bones
8.0
8.9
19
24
5BA08
NOMESCO Finland
NA
8.0
8.9
19
24
L01XX11
ATC
estramustine; systemic
9.5
8.8
17
18
KC1GB
NOMESCO Finland
Cystography with X-ray
3.3
8.7
41
125
C03CA01
ATC
furosemide; systemic
1.4
8.7
516
4052
HB000
NOMESCO Finland
Profylactic radiotherapy of mammary gland
11.6
8.6
15
13
WB201
NOMESCO Finland
Simple neoadjuvant hormone therapy of malignancy
27.7
8.5
11
*
8000/3-C61.9
ICD-O-3
Neoplasm, malignant of prostate gland
27.7
8.5
11
*
EB1CI
NOMESCO Finland
Cone beam imaging of teeth and jaws (3-4 quarters)
6.0
8.5
22
37
WGA10
NOMESCO Finland
Measurement of pain intensity
90.5
8.4
9
*
KH1AT
NOMESCO Finland
Urinary tract cathetrisation with ultrasound guidance
7.9
8.4
18
23
WB211
NOMESCO Finland
Neoadjuvant hormone therapy of malignancy
+∞
8.3
8
*
KED22
NOMESCO Finland
Transurethral resection of prostate
1.7
8.2
193
1230
R06AE07
ATC
cetirizine; oral
1.4
8.1
397
2996
WX290
NOMESCO Finland
Other blockade of nerve
1.4
8.1
432
3314
K10.25
ICD-10 Finland
Sequences of jawbones
8.2
8.1
17
21
SPAT1255
SPAT
Intravenous administration of medicine
1.9
8.1
119
653
SPAT1222
SPAT
Counselling/guidance promoting independent living
1.6
8.0
225
1501
U07
ICPC
Urine symptom/complaint other
2.1
7.9
83
401
N30.4
ICD-10 Finland
Irradiation cystitis
13.1
7.9
13
10
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
2.7
7.8
51
194
N02AA03
ATC
hydromorphone; systemic, rectal
9.5
7.8
15
16
SPAT1109
SPAT
Analgesia with portable analgesic pump
5.3
7.7
22
42
Z08.1
ICD-10 Finland
Follow-up examination after radiotherapy for malignant neoplasm
6.7
7.6
18
27
K10.20
ICD-10 Finland
Osteomyelitis (neonatal) of jaw (acute)(chronic)(suppurative)
11.9
7.6
13
11
R60.0
ICD-10 Finland
Localized oedema
1.7
7.6
163
1012
C79.39
ICD-10 Finland
Secondary malignant tumor of the meninges, ventricle or other part of the brain
25.1
7.6
10
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
3.1
7.6
39
128
G04CA01
ATC
alfuzosin; oral
1.5
7.5
339
2515
A07EA02
ATC
hydrocortisone; rectal
3.1
7.5
39
129
SAA02
NOMESCO Finland
Basic examination of mouth
1.4
7.3
671
5624
WX110
NOMESCO Finland
Local anesthesy
1.3
7.3
833
7224
-55
ICPC
Local injection/infiltration
5.2
7.2
21
41
YN1BD
NOMESCO Finland
Extensive CT examination of extremities for dose design of radiotherapy
15.8
7.2
11
7
SPAT1262
SPAT
Handing over of treatment supplies
1.5
7.2
320
2363
L28
ICPC
Limited function/disability (L)
1.5
7.1
232
1604
130
Kela drug reimbursment
Malignant tumour
0.5
7.0
53
1033
Z43.5
ICD-10 Finland
Attention to cystostomy
4.6
6.9
22
48
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
1.5
6.8
242
1705
WF029
NOMESCO Finland
Radiotherapy of local residive tumor
4.3
6.7
23
54
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
2.8
6.7
40
145
KA1AE
NOMESCO Finland
Kidney ultrasound examination
2.4
6.7
54
232
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
1.5
6.6
282
2064
N05CD07
ATC
temazepam; oral
0.6
6.5
72
1252
G04BD08
ATC
solifenacin; oral
1.8
6.4
102
579
AA1CD
NOMESCO Finland
Very extensive CT of head and brain
2.9
6.4
37
131
JN2BG
NOMESCO Finland
MRI examination of lower part of abdoment with high intensity magnet
6.6
6.3
15
23
JN2CM
NOMESCO Finland
Lower part of abdomen extensive MRI examination with Tesla magnet
5.2
6.3
18
35
A21
ICPC
Risk factor for malignancy
11.1
6.3
11
10
EDA10
NOMESCO Finland
Biopsy of mandible
11.1
6.3
11
10
2AE02
NOMESCO Finland
NA
18.1
6.3
9
5
U29
ICPC
Urinary symptom/complaint other
2.5
6.1
45
185
WVA20
SPAT
NA
4.2
6.1
21
50
NA3DG
NOMESCO Finland
Lumbar spine very extensive MRI examination with high intensity magnet
4.7
6.1
19
41
U50
ICPC
Urological, Medication/prescr/renewal
12.6
6.1
10
8
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
985
1752
11.64
307.65
2.8
2.0
2.2
13.0
nmol/l
251.29
812
1493
1433
8123
5.31
175.88
16.8
6.7
9.9
13.4
umol/l
40.85
1415
7752
1060
4912
3.96
172.12
11.2
3.3
2.3
2.3
mmol/l
0.02
995
4199
1658
11519
10.11
136.34
20.9
8.2
105.3
81.1
u/l
18.61
1635
10851
1337
8034
3.86
130.35
13.3
7.7
1.2
1.2
mmol/l
1.47
1133
6750
1467
9778
4.17
113.06
6.0
4.5
275.9
1059.5
e6/l
0.65
23
188
1329
8360
3.49
111.39
18.8
8.8
4.3
4.5
e9/l
2.95
1234
7245
1658
12227
8.38
108.78
19.8
5.4
36.7
3.2
ug/l
16.49
1604
10822
1174
7346
2.83
89.79
9.6
6.7
1.2
1.2
mmol/l
5.69
1112
6645
1091
7042
2.47
70.56
6.9
5.5
33.4
34.3
g/l
5.46
1040
6532
518
2407
2.64
68.45
7.0
4.0
281.1
239.4
u/l
4.22
500
2274
1360
9809
2.76
68.13
9.4
4.7
20.6
22.0
%
2.54
1048
5295
1058
6915
2.35
63.79
5.0
3.3
1.9
0.8
ug/l
19.58
861
5070
570
2861
2.47
63.22
6.0
3.3
2.5
2.5
mmol/l
0.60
539
2497
884
5406
2.29
61.73
4.7
3.7
152.0
103.6
e6/l
0.63
775
4352
1651
13796
4.77
54.49
28.8
18.9
32.3
30.2
mg/l
1.61
1531
11484
795
4864
2.17
52.96
4.4
3.6
0.5
0.5
e6/l
0.07
684
3808
667
3820
2.21
52.42
3.4
2.8
3.1
2.9
e6/l
0.29
613
3372
1016
6995
2.09
47.76
6.5
6.2
22.2
24.8
%
11.10
944
6475
306
1351
2.53
42.87
7.5
4.6
1.2
1.2
mmol/l
0.00
287
1200
544
3069
2.12
42.69
1.9
1.9
—
—
—
0
0
1015
7209
1.98
41.09
5.8
4.6
—
—
—
0
0
1661
14569
4.01
37.44
22.2
11.7
23.5
27.4
u/l
6.13
1629
13922
1686
14945
4.99
37.25
45.0
27.5
231.8
224.9
e9/l
4.10
1663
14501
1686
14947
4.98
37.20
44.9
27.5
4.1
4.5
e12/l
125.58
1660
14430
1686
14950
4.97
37.12
45.0
27.5
6.7
7.1
e9/l
4.48
1662
14433
1686
14951
4.97
37.10
45.2
27.7
123.8
136.2
g/l
156.73
1666
14681
1243
9685
1.99
35.91
5.2
5.4
7.0
7.0
mmol/l
0.37
1198
9182
1664
14725
3.90
34.58
31.0
22.7
139.2
139.6
mmol/l
7.64
1639
14377
1665
14751
3.91
34.29
31.5
23.0
4.0
4.0
mmol/l
1.21
1639
14391
1528
13053
2.39
31.92
33.3
18.0
76.4
72.6
ml/min/173m2
12.84
1432
10969
613
3927
1.87
31.44
3.2
2.7
—
—
—
0
0
481
2859
1.94
30.97
4.1
3.4
0.7
0.6
e6/l
0.29
326
1742
1024
7765
1.77
28.99
10.8
12.2
1.2
1.4
inr
9.05
306
2112
206
966
2.28
24.50
1.9
1.9
2.5
2.5
ug/l
0.00
185
847
473
3013
1.78
23.41
3.8
3.2
1.1
0.9
e6/l
0.85
315
1880
458
2904
1.78
22.96
3.2
3.4
0.8
0.8
mmol/l
0.34
441
2719
639
4461
1.68
22.57
2.0
2.2
3.1
3.0
mg/l
0.71
558
3783
644
4509
1.68
22.47
6.3
3.4
37.2
42.2
u/l
0.54
621
4280
354
2109
1.85
21.65
1.9
1.8
—
—
—
0
0
451
2892
1.75
21.55
2.3
2.8
11.8
12.5
umol/l
1.17
428
2692
351
2097
1.84
21.23
1.9
1.9
—
—
—
0
0
427
2711
1.76
21.06
2.1
2.8
2.1
2.2
g/l
5.85
397
2518
784
5860
1.61
20.58
3.5
3.3
1825.9
1902.1
ng/l
0.18
706
5189
216
1118
2.06
19.87
1.6
1.5
—
—
—
0
0
1018
8235
1.57
18.12
3.7
3.4
54.8
64.5
u/l
2.48
928
7490
1344
11624
1.68
18.03
31.0
20.3
35.5
39.0
%
18.36
801
6902
398
2575
1.71
17.98
2.2
2.9
23.1
23.1
%
0.00
340
2192
164
807
2.14
17.17
2.1
1.9
—
—
—
0
0
556
4006
1.57
16.00
5.4
4.4
87.5
79.3
%
11.00
548
3929
730
5630
1.51
15.17
2.5
3.0
481.6
198.5
ug/l
13.02
667
5102
209
1173
1.89
15.08
1.7
1.7
—
—
—
0
0
148
747
2.07
14.47
2.0
1.8
—
—
—
0
0
291
1886
1.65
12.64
2.9
4.3
21.4
29.7
ug/l
0.34
240
1606
60
214
2.87
12.61
2.2
1.2
—
—
—
0
0
823
6665
1.45
12.55
4.2
4.3
76.1
64.1
ng/l
0.15
717
5429
856
6985
1.44
12.52
4.1
3.7
0.0
0.0
estimate
0.00
212
1299
367
2532
1.57
12.28
5.9
7.2
104.3
104.6
mmol/l
0.60
360
2465
840
6853
1.44
12.17
5.5
4.8
0.0
0.0
estimate
0.00
223
1388
1239
10875
1.48
12.07
39.6
22.9
14.5
13.9
%
27.98
1229
10620
82
350
2.41
12.06
1.8
3.9
2.5
1.8
%
0.55
54
265
43
132
3.31
11.67
2.6
1.2
180.5
52.4
u/l
1.89
35
88
31
81
3.88
10.67
2.7
1.6
3.6
7.6
u/l
1.00
22
41
621
4909
1.41
10.19
2.6
2.7
51.0
59.2
u/l
6.16
585
4538
270
1809
1.58
10.11
3.1
3.0
229.9
248.2
ng/l
0.22
254
1660
354
2522
1.51
10.03
2.7
2.4
1.8
1.7
%
0.95
321
2218
95
468
2.09
9.94
1.2
1.6
—
—
—
0
0
749
6132
1.39
9.92
2.3
2.1
—
—
—
0
0
260
3732
0.64
9.63
1.6
1.7
1.5
1.3
mmol/l
2.39
200
3032
826
6909
1.37
9.43
4.1
3.6
0.0
0.0
estimate
0.00
225
1356
200
1290
1.62
8.73
1.5
1.7
—
—
—
0
0
266
1860
1.51
8.12
3.3
4.1
5.6
5.8
kpa
3.89
259
1793
266
1863
1.50
8.06
3.3
4.1
1.7
1.8
mmol/l
0.31
204
1464
86
450
1.96
7.68
1.3
1.6
—
—
—
0
0
52
224
2.36
7.59
1.8
4.1
62.3
58.7
%
0.43
30
139
532
4276
1.35
7.35
1.8
1.6
17.0
18.9
nmol/l
2.34
461
3643
74
374
2.02
7.30
1.6
1.3
—
—
—
0
0
74
374
2.02
7.30
1.6
1.3
—
—
—
0
0
332
2479
1.42
7.16
4.6
6.9
1.0
1.0
mmol/l
0.06
311
2329
639
5318
1.32
6.85
4.6
4.0
—
—
—
0
0
97
550
1.81
6.80
1.2
1.3
—
—
—
0
0
461
5661
0.75
6.52
3.2
3.3
7.4
8.1
mmol/l
4.21
358
4681
247
1779
1.45
6.45
3.5
3.0
7.3
11.2
umol/l
3.20
223
1608
22
65
3.42
6.42
1.2
1.1
36.8
44.6
u/l
0.22
17
43
77
427
1.84
5.84
3.9
3.6
7.1
7.7
mmol/l
1.46
77
413
427
3422
1.33
5.81
4.1
4.3
246.2
721.5
ng/l
1.19
380
3057
252
1872
1.40
5.53
3.8
3.9
—
—
—
0
0
497
5937
0.77
5.48
4.0
4.2
8.7
10.9
mg/mmol
0.75
328
4088
26
97
2.71
5.18
1.2
1.8
—
—
—
0
0
26
97
2.71
5.18
1.2
1.8
—
—
—
0
0
26
97
2.71
5.18
1.2
1.8
—
—
—
0
0
26
97
2.71
5.18
1.2
1.8
—
—
—
0
0
188
1353
1.44
4.93
2.4
2.5
29.5
41.3
u/l
1.64
162
1161
43
207
2.10
4.92
1.4
1.5
—
—
—
0
0
28
112
2.52
4.88
1.7
3.1
—
—
—
0
0
62
341
1.85
4.87
1.4
1.7
—
—
—
0
0
369
2967
1.31
4.81
1.6
1.7
2.4
1.6
mg/l
2.14
308
2375
44
216
2.06
4.80
1.4
1.7
—
—
—
0
0
43
211
2.06
4.70
1.4
1.5
—
—
—
0
0
43
212
2.05
4.64
1.4
1.5
—
—
—
0
0
77
466
1.68
4.40
2.6
2.6
15.3
16.0
%
0.99
40
253
477
4009
1.26
4.34
4.5
3.9
0.0
0.0
estimate
0.20
198
1243
255
1975
1.34
4.30
5.6
7.8
11.1
11.6
mmol/l
0.50
238
1872
179
1316
1.40
4.18
3.0
3.8
1.7
1.8
mmol/l
0.04
126
933
582
5035
1.23
4.04
2.0
2.1
81.7
76.5
nmol/l
3.82
513
4341
41
211
1.97
3.98
1.4
1.5
—
—
—
0
0
41
213
1.95
3.88
1.4
1.5
—
—
—
0
0
41
213
1.95
3.88
1.4
1.5
—
—
—
0
0
87
1307
0.65
3.83
1.7
1.7
1.6
1.8
%
1.22
73
1063
184
1389
1.36
3.68
3.1
3.9
5.0
5.1
kpa
1.25
171
1282
128
913
1.43
3.57
2.6
4.3
23.5
23.9
mmol/l
1.08
118
804
118
1645
0.70
3.55
1.2
1.2
15.7
13.0
u/ml
0.10
31
558
48
275
1.77
3.40
1.4
1.6
—
—
—
0
0
144
1066
1.38
3.27
1.4
1.7
1.9
1.5
g/l
3.20
116
910
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
119
854
1.42
3.23
2.8
2.8
0.4
0.3
u/ml
0.59
71
477
114
819
1.42
3.09
3.0
4.4
24.5
24.7
mmol/l
0.23
102
752
193
1509
1.31
3.07
2.8
3.2
4.1
4.5
kpa
2.72
183
1451
56
346
1.64
3.05
1.3
1.4
—
—
—
0
0
31
160
1.95
3.05
1.3
1.6
—
—
—
0
0
56
347
1.63
3.02
1.4
1.4
—
—
—
0
0
48
286
1.70
3.00
3.2
3.5
60.2
58.4
%
0.42
48
286
52
317
1.66
2.99
1.2
1.4
—
—
—
0
0
70
460
1.54
2.96
2.4
2.2
123.5
128.4
g/l
0.97
55
339
7
209
0.33
2.93
1.0
1.1
—
—
—
0
0
133
1756
0.74
2.90
1.2
1.2
31.4
39.7
iu/ml
0.40
40
482
35
192
1.84
2.89
1.2
1.6
—
—
—
0
0
24
116
2.08
2.83
1.3
1.6
—
—
—
0
0
18
77
2.35
2.82
1.3
1.9
—
—
—
0
0
36
202
1.80
2.78
1.2
1.6
—
—
—
0
0
28
145
1.95
2.75
1.5
1.7
—
—
—
0
0
47
288
1.65
2.68
1.3
1.4
—
—
—
0
0
0
68
0.00
2.60
0.0
1.1
—
—
—
0
0
46
283
1.64
2.59
1.2
1.4
—
—
—
0
0
410
4684
0.84
2.56
2.8
3.2
5677.9
6097.6
umol/l
0.03
333
3989
17
75
2.28
2.51
1.3
1.9
—
—
—
0
0
17
75
2.28
2.51
1.3
1.9
—
—
—
0
0
23
116
2.00
2.46
1.3
1.6
—
—
—
0
0
26
138
1.90
2.41
1.3
1.8
1.8
1.4
u/field
—
5
47
26
138
1.90
2.41
1.2
1.5
—
—
—
0
0
31
526
0.58
2.38
2.1
1.9
—
—
—
0
0
171
2116
0.79
2.32
1.2
1.2
0.9
2.1
u/ml
2.83
28
517
31
178
1.76
2.27
1.2
1.6
—
—
—
0
0
31
178
1.76
2.27
1.2
1.6
—
—
—
0
0
31
178
1.76
2.27
1.2
1.6
—
—
—
0
0
405
3553
1.18
2.26
2.0
1.8
1225.3
1152.3
nmol/l
0.71
311
2666
862
9210
0.87
2.13
3.2
3.1
15.1
15.0
pmol/l
0.39
752
8079
43
277
1.57
2.07
3.2
3.3
4.4
4.4
e9/l
0.00
43
277
9
209
0.43
2.07
1.9
1.5
10.3
13.3
u/l
—
9
200
46
302
1.54
2.04
1.3
1.3
—
—
—
0
0
558
5059
1.15
2.01
2.7
2.2
216.2
258.1
u/l
0.51
530
4725
14
64
2.20
1.94
1.4
1.5
—
—
—
0
0
1105
10504
1.14
1.94
3.2
4.1
21.6
13.8
mm/h
22.31
1001
9602
46
307
1.51
1.91
5.2
6.7
13.0
11.9
mg/l
0.75
40
288
37
239
1.56
1.79
2.2
2.1
19.7
25.4
mg/l
—
10
47
409
3656
1.16
1.78
2.2
1.8
415.5
26380974.0
pmol/l
2.84
344
3006
16
298
0.53
1.77
1.1
1.4
11.8
39.6
e6/l
0.70
11
235
16
298
0.53
1.77
1.4
1.3
—
—
—
0
0
743
6914
1.13
1.76
2.0
2.1
88.1
90.3
pmol/l
0.65
457
3985
140
1137
1.25
1.74
2.3
4.7
119.5
111.6
ng/l
0.24
120
990
0
47
0.00
1.70
0.0
1.3
—
—
—
0
0
24
141
1.71
1.68
1.4
1.5
—
—
—
0
0
24
392
0.61
1.66
1.0
1.0
—
—
—
0
0
347
3084
1.16
1.63
2.2
2.0
30.3
30.3
s
0.02
336
2993
18
99
1.83
1.57
2.3
4.4
78.8
168.8
nmol/l
1.17
18
99
320
2838
1.16
1.55
28.6
30.4
1.3
1.5
inr
2.13
58
402
24
145
1.66
1.54
1.3
1.4
—
—
—
0
0
235
2039
1.18
1.51
4.2
5.0
31.8
32.5
%
0.39
158
1355
5
127
0.39
1.49
1.0
1.1
—
—
—
0
0
178
2085
0.84
1.47
10.2
8.3
—
—
—
0
0
23
140
1.65
1.45
1.4
1.5
—
—
—
0
0
19
110
1.74
1.43
1.5
1.5
—
—
—
0
0
19
110
1.74
1.43
1.5
1.5
—
—
—
0
0
33
482
0.68
1.41
1.7
1.7
44.9
47.2
nmol/l
0.26
33
450
6
23
2.61
1.37
1.8
2.5
—
—
—
0
0
0
37
0.00
1.34
0.0
11.0
—
5.6
—
0
37
20
321
0.62
1.34
1.3
1.3
—
—
—
0
0
19
307
0.61
1.31
1.2
1.3
—
—
—
0
0
15
83
1.81
1.31
1.3
1.3
2.3
2.7
u/field
—
7
55
6
24
2.51
1.30
1.2
1.2
—
—
—
0
0
6
24
2.51
1.30
1.8
2.4
—
—
—
0
0
42
574
0.73
1.26
1.7
2.4
58.1
114.6
ug/min
1.59
22
344
201
1750
1.17
1.26
4.2
7.2
1.3
1.4
mmol/l
2.31
191
1686
8
38
2.11
1.18
1.1
1.2
—
—
—
0
0
17
272
0.62
1.15
1.2
1.5
—
—
—
0
0
1363
13291
1.12
1.14
6.5
7.1
41.9
41.6
mmol/mol
0.32
1228
12075
10
181
0.55
1.08
1.2
1.1
—
33.4
—
0
11
1351
13821
0.90
1.07
4.7
5.6
2.5
2.4
mmol/l
4.66
1168
12442
74
599
1.25
1.03
3.1
3.3
24.5
24.7
mmol/l
0.09
66
520
12
203
0.59
1.03
2.0
1.7
326.8
298.2
mu/l
0.16
12
193
5
109
0.46
1.00
1.0
1.2
—
—
—
0
0
64
512
1.26
0.99
1.3
1.5
—
—
—
0
0
1393
13635
1.11
0.97
4.8
5.3
6.3
6.2
mmol/l
0.66
1217
12143
111
1295
0.85
0.94
5.8
9.3
93.3
93.8
%
0.35
111
1289
194
1729
1.14
0.93
3.4
2.6
65.0
65.8
g/l
0.72
166
1579
9
52
1.73
0.92
3.7
2.0
—
—
—
0
0
113
969
1.18
0.91
1.1
1.2
—
—
—
0
0
14
218
0.64
0.89
1.8
1.3
10.4
14.2
u/l
0.83
14
202
1303
13316
0.91
0.88
4.4
5.0
1.3
1.3
mmol/l
2.65
1130
11941
24
331
0.72
0.83
1.4
1.2
0.9
0.8
nmol/l
0.39
17
274
46
576
0.79
0.81
1.6
1.6
38.5
36.5
u/l
0.29
39
481
150
1331
1.14
0.79
5.9
3.0
60.4
59.1
ml/min/173m2
0.19
69
573
16
235
0.68
0.79
1.3
1.4
—
—
—
0
0
11
66
1.67
0.78
1.3
2.3
—
—
—
0
0
11
66
1.67
0.78
1.3
2.3
—
—
—
0
0
17
246
0.69
0.78
1.1
1.1
—
—
—
0
0
60
722
0.82
0.75
1.6
3.5
119.7
68.4
mg/l
0.28
50
582
102
886
1.16
0.73
2.2
2.7
0.7
0.7
%
0.70
97
848
59
709
0.83
0.73
1.6
3.5
2.0
3.0
ratio
—
5
53
57
470
1.22
0.73
1.4
2.6
30.3
35.2
umol/l
0.73
48
386
21
287
0.73
0.71
1.1
1.1
—
43.2
—
0
10
12
77
1.56
0.68
2.1
2.1
—
—
—
0
0
1271
12954
0.93
0.67
4.0
4.5
1.4
1.3
mmol/l
4.90
1095
11539
80
688
1.17
0.67
3.2
3.7
236.9
7305.9
u/ml
1.04
67
582
5
91
0.55
0.67
1.0
1.1
—
—
—
0
0
61
721
0.84
0.65
1.6
3.5
230.1
54.4
mg/l
0.45
52
587
20
270
0.74
0.64
1.6
1.4
305.6
349.7
u/l
0.32
20
258
28
359
0.78
0.63
1.3
1.6
—
—
—
0
0
8
49
1.64
0.62
7.4
5.7
13.5
13.4
%
—
8
49
1322
13441
0.93
0.62
4.3
5.0
4.4
4.2
mmol/l
9.81
1145
12195
178
1626
1.11
0.61
1.9
2.3
0.2
0.2
g/l
0.36
164
1490
47
564
0.83
0.60
1.4
1.3
384.7
277.5
u/ml
0.21
42
508
0
20
0.00
0.60
0.0
6.8
—
—
—
0
0
67
778
0.86
0.60
2.8
2.7
—
—
—
0
0
0
22
0.00
0.59
0.0
4.9
—
—
—
0
0
26
201
1.30
0.59
1.2
1.5
71.7
65.6
%
0.37
18
121
8
53
1.51
0.58
1.0
1.2
—
—
—
0
0
5
86
0.58
0.56
1.2
1.1
—
—
—
0
0
182
1976
0.91
0.56
5.3
8.1
113.0
122.0
g/l
8.15
176
1902
6
97
0.62
0.52
1.3
1.4
16.9
16.3
umol/l
—
6
89
7
46
1.52
0.48
1.6
1.1
—
—
—
0
0
19
146
1.30
0.47
1.4
1.3
—
—
—
0
0
8
117
0.68
0.46
2.4
3.2
—
—
—
0
0
5
83
0.60
0.45
1.2
1.2
—
—
—
0
0
28
341
0.82
0.45
1.9
1.8
107.4
203.8
pmol/l
4.10
22
312
7
50
1.40
0.45
1.7
2.0
—
—
—
0
0
173
1853
0.93
0.42
2.8
2.4
4.7
8.2
ug/l
5.25
152
1635
39
456
0.85
0.42
3.0
2.8
1.9
1.8
mg/l
0.17
34
400
0
15
0.00
0.41
0.0
1.0
—
1.3
—
0
8
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
54
613
0.88
0.40
3.0
3.9
3.9
4.0
mmol/l
0.48
47
563
13
171
0.76
0.39
1.0
1.2
—
—
—
0
0
5
35
1.43
0.39
1.6
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.0
—
—
—
0
0
1188
12048
0.96
0.37
3.7
4.0
2.1
2.1
mu/l
0.07
1032
10636
48
422
1.14
0.36
2.2
3.4
54.7
711.0
u/ml
1.61
41
394
6
42
1.43
0.35
1.0
1.2
—
—
—
0
0
13
99
1.32
0.35
2.1
2.3
—
—
—
0
0
37
321
1.16
0.33
1.2
1.2
—
—
—
0
0
11
144
0.76
0.33
1.1
1.3
—
—
—
0
0
122
1309
0.93
0.33
5.4
6.8
23.8
24.3
mmol/l
0.46
114
1220
38
434
0.87
0.32
1.4
1.6
13703.5
15441.1
e6/l
0.18
28
306
59
534
1.11
0.30
1.2
2.5
0.0
0.0
g/l
0.00
48
495
12
152
0.79
0.29
1.6
1.2
2.2
6.1
u/ml
—
5
71
8
110
0.73
0.29
1.5
1.2
90.4
90.7
%
—
8
100
36
317
1.14
0.28
1.2
1.2
—
—
—
0
0
8
66
1.21
0.26
1.1
1.1
—
—
—
0
0
37
414
0.89
0.25
3.3
3.0
0.8
0.8
nmol/l
0.08
23
310
35
393
0.89
0.25
1.3
1.6
—
—
—
0
0
45
497
0.90
0.25
1.3
1.4
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
9
77
1.17
0.24
1.0
1.1
—
—
—
0
0
56
513
1.09
0.24
3.6
3.5
4.4
4.3
pmol/l
0.24
51
446
32
360
0.89
0.24
1.2
1.2
—
258.3
—
0
12
5
41
1.22
0.22
1.0
1.0
—
—
—
0
0
5
41
1.22
0.22
1.0
1.0
—
—
—
0
0
5
41
1.22
0.22
1.0
1.0
—
—
—
0
0
5
42
1.19
0.21
1.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
9.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
8.2
—
—
—
0
0
59
546
1.08
0.21
1.2
2.5
0.0
0.0
g/l
0.50
48
495
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
63
585
1.08
0.21
1.2
2.5
0.0
0.0
g/l
0.01
52
533
0
13
0.00
0.21
0.0
1.7
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
2.4
—
—
—
0
0
13
108
1.21
0.20
3.4
2.0
348.7
593.2
e6/l
—
7
50
26
292
0.89
0.20
2.5
1.6
—
—
—
0
0
6
50
1.20
0.19
1.3
2.6
7.4
8.5
mmol/l
—
6
28
13
154
0.84
0.19
2.5
1.3
0.8
0.7
nmol/l
0.63
13
145
32
290
1.11
0.18
2.5
1.3
7.3
7.7
u/l
0.07
17
233
10
121
0.83
0.18
1.0
1.1
3.0
2.1
mmol/l
—
10
109
7
62
1.13
0.17
1.0
1.1
—
—
—
0
0
42
388
1.08
0.17
3.9
3.5
35.4
34.8
mg/l
0.04
30
253
232
2386
0.97
0.16
4.9
7.3
11.4
11.8
kpa
0.70
220
2275
232
2385
0.97
0.16
4.9
7.3
4.8
5.1
kpa
3.20
219
2272
11
92
1.20
0.16
1.0
1.3
—
—
—
0
0
11
92
1.20
0.16
1.0
1.3
—
—
—
0
0
6
77
0.78
0.15
1.0
1.3
—
—
—
0
0
71
673
1.06
0.15
1.5
2.7
1.2
1.4
g/l
0.14
54
574
27
296
0.91
0.15
1.2
1.1
—
—
—
0
0
21
188
1.12
0.14
1.4
1.7
4.7
4.5
iu/l
—
8
58
41
438
0.93
0.13
1.1
1.2
93.6
117.5
iu/ml
0.25
14
131
10
117
0.85
0.13
1.1
1.1
—
—
—
0
0
9
107
0.84
0.13
1.0
1.0
—
—
—
0
0
63
600
1.05
0.12
1.2
2.4
35.3
37.1
g/l
1.49
48
518
10
116
0.86
0.12
1.2
1.3
—
32.5
—
0
8
233
2380
0.98
0.12
4.9
7.3
0.8
1.0
mmol/l
0.27
175
1815
12
105
1.14
0.11
3.0
2.2
377.8
540.5
e6/l
0.63
12
93
31
332
0.93
0.11
1.5
1.5
1508.9
1826.8
e6/l
0.34
26
240
52
495
1.05
0.10
1.4
1.6
—
—
—
0
0
5
44
1.14
0.10
1.0
1.0
—
—
—
0
0
5
45
1.11
0.09
1.0
1.0
—
—
—
0
0
308
3126
0.98
0.09
4.7
4.1
1.0
1.0
kg/l
0.58
66
491
20
217
0.92
0.09
1.1
1.1
1.2
32.0
iu/ml
—
6
40
32
301
1.06
0.09
1.2
1.1
—
—
—
0
0
20
185
1.08
0.08
1.3
1.5
—
—
—
0
0
40
381
1.05
0.08
1.2
1.2
—
—
—
0
0
6
75
0.80
0.07
1.0
1.3
—
55.8
%
—
0
12
77
790
0.97
0.06
1.4
2.5
8.5
7.3
g/l
2.90
50
585
20
213
0.94
0.06
4.3
3.5
—
—
—
0
0
77
789
0.97
0.05
1.4
2.5
—
—
—
0
0
77
788
0.98
0.05
1.4
2.5
4.4
3.8
g/l
0.54
49
566
29
303
0.96
0.05
1.5
1.5
55343.8
67532.9
e6/l
0.12
18
187
75
734
1.02
0.04
1.5
2.5
9.6
10.5
g/l
1.06
54
621
114
1122
1.02
0.04
5.5
9.4
23.6
24.2
mmol/l
0.96
106
1050
44
427
1.03
0.04
1.4
1.5
266.3
248.1
ug/g
0.28
30
279
11
119
0.92
0.04
1.1
1.3
—
—
—
0
0
13
139
0.93
0.03
1.3
1.1
—
—
—
0
0
24
230
1.04
0.03
1.2
1.2
316.6
281.6
u/ml
0.23
11
136
26
252
1.03
0.02
1.2
1.2
—
—
—
0
0
11
103
1.07
0.02
1.0
1.1
—
31.6
—
0
5
56
552
1.01
0.01
1.5
1.8
—
—
—
0
0
11
104
1.06
0.01
1.6
2.3
—
—
—
0
0
10
99
1.01
0.00
2.6
2.2
0.2
0.2
e9/l
—
10
92
19
185
1.03
0.00
1.7
3.2
—
—
—
0
0
28
285
0.98
0.00
1.3
1.4
—
20.7
—
0
9
73
728
1.00
0.00
1.5
2.5
3.7
3.0
g/l
3.83
50
574
12
118
1.02
0.00
1.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
4.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
4.8
—
342.8
—
0
6
5
53
0.94
0.00
1.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
65.5
—
0
6
13
130
1.00
0.00
1.4
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
842.0
—
0
5
0
5
0.00
0.00
0.0
7.2
—
67.6
—
0
5
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
8
85
0.94
0.00
1.0
1.0
—
—
—
0
0
7
74
0.95
0.00
2.1
1.4
28.7
24.1
%
—
7
57
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
24
240
1.00
0.00
1.3
1.5
107.3
120.0
u/ml
—
6
54
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
9
92
0.98
0.00
3.7
1.8
—
—
—
0
0
7
75
0.93
0.00
1.0
1.1
—
—
—
0
0
6
66
0.91
0.00
1.0
1.2
86.3
259.4
iu/ml
—
6
66
7
79
0.89
0.00
1.4
1.6
11.0
13.7
nmol/l
—
7
70
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
2.0
—
0
5
0
5
0.00
0.00
0.0
1.8
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: RX_L02BX – L02BX Other hormone antagonists and related agents
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).